Objectives. In 2016, the Second Panel on Cost-effectiveness in Health and Medicine updated the seminal work of the original panel from 2 decades earlier. The Second Panel had an opportunity to reflect on the evolution of costeffectiveness analysis (CEA) and to provide guidance for the next generation of practitioners and consumers. In this article, we present key topics for future research and policy. Methods. During the course of its deliberations, the Second Panel discussed numerous topics for advancing methods and for improving the use of CEA in decision making. We identify and consider 7 areas for which the panel believes that future research would be particularly fruitful. In each of these areas, we highlight outstanding research needs. The list is not intended as an exhaustive inventory but rather a set of key items that surfaced repeatedly in the panel's discussions. In the online Appendix, we also list and expound briefly on 8 other important topics. Results. We highlight 7 key areas: CEA and perspectives (determining, valuing, and summarizing elements for the analysis), modeling (comparative modeling and model transparency), health outcomes (valuing temporary health and path states, as well as health effects on caregivers), costing (a cost catalogue, valuing household production, and productivity effects), evidence synthesis (developing theory on learning across studies and combining data from clinical trials and observational studies), estimating and using costeffectiveness thresholds (empirically representing 2 broad concepts: opportunity costs and public willingness to pay), and reporting and communicating CEAs (written protocols and a quality scoring system). Conclusions. Costeffectiveness analysis remains a flourishing and evolving field with many opportunities for research. More work is needed on many fronts to understand how best to incorporate CEA into policy and practice.
In the 20 years since publication of the report of the original US Panel on Cost-effectiveness in Health and Medicine, 1 researchers have continued to advance methods of cost-effectiveness analysis (CEA), and policy makers have applied CEA in various settings. Updating the original panel's work provided the Second Panel on Cost-effectiveness in Health and Medicine (hereafter the ''Second Panel'') an opportunity to reflect on the evolution of CEA and to provide guidance for the next generation of practitioners and consumers. 2 It also identified key areas for future research and policy development. While the Second Panel's report touched on certain items for future work, it devoted relatively little space to them and did not include a dedicated chapter on the topic.
Selection of Topics
In this article, members of the Second Panel elaborate on selected areas, highlighting several important topics that arose during its deliberations and for which the Second Panel believes that future research would be particularly fruitful. In particular, these are topics for which the Second Panel anticipates material progress in the next 10 or so years and believes that efforts would help improve medical and policy decisions. This list is not intended as an exhaustive inventory but rather a set of key items that surfaced repeatedly in the Second Panel's discussions, for which methods development is active and for which the Second Panel believes that attention would be important. We focus on 7 areas, following the sequence of topics as they appeared in the Second Panel's report: 1) CEA and perspectives, 2) modeling, 3) valuing health outcomes, 4) costing and valuing nonhealth consequences, 5) evidence synthesis, 6) estimating and using CEA thresholds, and 7) reporting and communicating CEAs. We recognize that the list is somewhat subjective and that other observers might prioritize differently. Our hope is that the article provides a constructive guide for the field going forward. In the online Appendix, we list and briefly discuss 8 other topics worthy of further research: 1) broadening criteria used to assess cost-effectiveness; 2) discounting; 3) incorporating uncertainty and value of information analysis; 4) assessing comparability, durability, and usefulness of CEA; 5) incorporating implementation and delivery aspects; 6) value-based pricing; 7) CEA and budget impact analysis; and 8) CEA and innovation. Finally, we acknowledge that other topics such as ethical considerations in CEA are also important but not addressed here.
Key Areas for Further Work

CEA and Perspectives
The original panel and Second Panel both recommended that analysts should perform a reference-case analysis following a set of standard methodological practices to improve the comparability and quality of CEAs.
1,2 Both panels recommended that reference case analyses report results from a societal perspective-reflecting the viewpoint of a decision maker whose intention is to allocate health resources optimally across the entire population. The Second Panel advanced the societal perspective by developing the concept of an Impact Inventory, a structured table listing an intervention's health and non-health consequences (with the latter including, for example, consequences on economic productivity, social services, criminal justice, education, housing, or the environment) that should be considered in a societal reference-case analysis. 3 The Second Panel also recommended the narrower health care sector perspective because it aligns more closely with many decision makers' viewpoints and reflects the existing practice of many CEAs. 4 Many issues require work before the field can reach agreement on summary measures for a societal perspective, particularly which elements to include in a summary, how these should be determined, and how to value them. The goal is to include elements that are mutually exclusive and collectively exhaustive. Acknowledging that there are no widely agreed-on methods for quantifying and valuing some of these broader consequences in CEA, the Second Panel did not endorse a single specific summary measure for the societal perspective. The report, however, emphasized that decision makers would be aided by the quantification and valuation of this wider range of effects in a summary measure, such as incremental cost-effectiveness ratios, net monetary benefits, or net health benefits. 3 Other questions include whether an analysis from a societal perspective should consider its primary goal to be health or some more general social welfare function that includes the effects of health, such as more schooling and more paid and unpaid work. Another question is whether preference weights in quality-adjusted life years (QALYs) reflect individuals' preferences for health only or also the effects of health-so that explicitly measuring and valuing these products outside of QALYs might be double counting. The framework offered by cost-benefit analysis (CBA)-which considers the value of costs and benefits to the losers and gainers of an intervention based on market prices and, when these are not available, shadow prices-already exists for the evaluation of programs and policies with different kinds of benefits and costs.
Researchers have spent decades considering what benefits and costs to measure and how to value them so they can be summarized, although questions remain about the use and impact of different methods and normative judgments. 5 A critical question is whether CEA needs its own framework or whether CEA from the societal perspective is simply a version of cost-benefit analysis (CBA), and thus the guidelines for CBA may apply (e.g., US Environmental Protection Agency 6 and US Office of Management and Budget 7 ). Alternatively, it may be appropriate to avoid too much focus on these classifications and instead move to a more flexible set of analytical methods that adopt elements of each and the nature of the decision context. 8 An important next step will be to advance the conceptual and theoretical framework in which to place those elements, a necessary precursor to summarizing them. As an example of new work in the area, recently, a series of the reports from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Special Task Force on US value assessment frameworks have described a health economics approach to conceptualize value under different decision contexts and to identify novel elements of value.
9,10
Modeling
Methodological development is important in several areas related to modeling in CEA, 11 including 1) comparative modeling and structural sensitivity analysis, 2) emulators of models, and 3) model transparency.
Comparative modeling and structural sensitivity analysis. Comparative modeling explores alternative choices about model structure by contrasting results of 2 or more models applied to the same context. The method has been adopted by researchers in the Cancer Intervention and Surveillance Modeling Network (CISNET), a consortium of cancer modelers involved with several policy-relevant analyses (cisnet.cancer.gov). Comparative modeling may be viewed as one way to conduct structural sensitivity analysis. However, no practical tools or processes exist to formally describe and quantify structural uncertainties or their impact. 12 Efforts to interpret results from multiple models with a goal of identifying strategies that perform well under all models are a start, 13 but preferred strategies often differ across models.
14 Approaches for how best to provide clear recommendations to policy makers when modeling results disagree are lacking. Another gap is that the ''similarity'' between 2 models is not easy to characterize. With comparative modeling, we implicitly assume that independently developed models reflect an adequate range of all possible combinations of structural assumptions. However, in practice, this may not be the case, and it may be difficult to determine the extent to which there is substantial overlap of structural assumptions between any 2 models (e.g., the degree of similarity). Models that are too similar are redundant and offer little to comparative modeling (i.e., they do not represent an adequate structural sensitivity analysis).
Emulators of models. Many CEA models are computationally demanding to evaluate. With typical hardware, computation time for analyses that require many model runs can become impractically long. Model emulators or meta-models, which are fast-to-run statistical approximations of simulation models, can be used to mitigate these computational costs. 15 Practical approaches are needed to efficiently develop well-performing emulators and to use emulators in various stages, including model development (e.g., expediting model calibration), analysis (e.g., expediting uncertainty propagation or value of information), and dissemination of results (e.g., deploying webaccessible of versions that can be tailored to users or help users build intuition about the model's behavior).
Model transparency. Issues regarding model transparency and trust, as well as approaches to facilitating model sharing, continue to be important. Current recommendations state that modelers should provide enough detail about model structure and parameterization to allow reproducibility. 16, 17 There is a need to determine how best to make models' structure and output available and understandable to users. Possible approaches range from making entire models available to providing versions that allow users to vary selected inputs. Some observers have called for open-source CEA, including publication of the model code. 18 They argue that releasing code would be keeping in line with other fields that require public data sharing. The Second Panel did not reach a consensus on this issue, although it supports ongoing work in the area and notes that there remain important unanswered questions for how best to implement an open-source environment for CEA models. What is the expected burden on the model developers to assist users in becoming familiar with an open-source model? What are the potential conflicts of interest? What are the potential downsides to releasing code directly to the public?
Valuing Health Outcomes
A variety of topics related to valuing health outcomes were discussed at length in Chapter 7 of the Second Panel's report and accompanying online appendices, such as multiattribute utility functions to provide scoring systems and alternative approaches. 19, 20 Here, we identify several issues for future research. Many of these arise because the analyst has evidence or suspects that important consequences would not be captured fully using standard methods. More specifically, we elaborate on issues pertaining to temporary health states and the related issue of path states, as well as spillover effects. We also briefly touch upon additional topics.
Temporary health states and path states. An illustration of the issues associated with temporary health states and path states can be found in studies of the health-related quality of life (HRQL) associated with decision making regarding prenatal diagnosis, where the process of prenatal diagnosis consists of a series of temporary health states resulting in a chronic outcome (a path). [21] [22] [23] In such contexts, analysts have assumed that the use of generic preference-based measures would likely miss many potentially important HRQL effects such as the anxiety of deciding whether or not to be tested. To avoid this problem, analysts have used the direct approach for eliciting preferences for both hypothetical and subjectively defined current health states, some describing temporary health states associated with the processes of an intervention and some describing chronic health states associated with the outcomes. (Methods for assessing temporary health states, especially chaining methods, are discussed elsewhere. 19, [24] [25] [26] ) One of the motivations for relying on the direct approach is that relatively few subjects are likely to experience a number of the health states (e.g., the consequences of a false-positive test result), and thus to populate a decision model, it is necessary to elicit preferences for these low-frequency states as hypothetical states. For temporary health states, if one uses the chronic healthstate standard gamble anchors of dead and perfect health, most subjects are unwilling to entertain any probability other than 1.0 for perfect health. Instead, subjects were asked to compare health states associated with the process of prenatal diagnosis to a temporary health state of the same duration based on a description of the experience of undergoing chemotherapy (but not so labeled). A chronic version of the chemotherapy state was assessed on the dead-perfect health scale to support the valuation of the temporary health states.
The nature of the clinical context called for the evaluation of temporary health states for the first (decide whether to be tested or not; undergo test), second (wait for results), and third trimesters and chronic health states associated with the outcomes of prenatal diagnosis (a true negative, a false negative, a true positive, a false positive, etc.). In the QALY model, each health state is weighted by its duration to estimate the value of the whole experience. However, the QALY model imposes strong assumptions that, for instance, the subject is indifferent to the sequence of events and weights health states proportional to their duration. Kuppermann et al. 22 asked subjects to evaluate temporary and chronic health states separately (QALY model) and also to evaluate path states, a combined description covering the 3 trimesters and chronic outcome. They then compared the QALY estimate to the value assigned to the path state. In general, the scores did not agree. 22 In this prenatal diagnosis study, subjects assigned greater weight to health states experienced in the first trimester and to health states associated with the chronic outcome than did their duration in the QALY model and less weight to the health states associated with the second and third trimesters. The greater emphasis on the first trimester makes clinical sense in that much of the decision making and undergoing procedures occurs then. In contrast, in a Patient Outcomes Research Teams study of knee replacement at Indiana University, the QALY model and path state scores agreed.
The prenatal diagnosis example highlights the potential importance in some contexts of valuing temporary health states and valuing path states. Yet few studies have compared the QALY approach to the path-state approach. More evidence and the exploration of improved methods to handle these situations are needed. One disadvantage of the path-state approach is that clinical evidence usually reports the incidence of major events but not necessarily the underlying paths. The routine prospective use of HRQL measures in patient registries could address this issue.
Health effects on caregivers. A number of studies have documented important effects of a family member's illness on the health of caregivers. 27, 28 Spillover effects can include effects on the physical health of the caregiver, as well as on the HRQL of the caregiver and other family members. [29] [30] [31] [32] The Second Panel recommended that spillover effects be included in the health care sector and societal perspectives, recognizing that the methods for measuring these effects and, in particular, valuing them need further methodological and ethical investigation and that including spillover effects may create the potential for double counting.
Additional issues. The field would also benefit from more assessment of the performance of different measurement approaches for eliciting preference scores. For instance, would using virtual reality experiments improve respondents' understanding of the nature of the health states and their consequences? The relationships among measures, as well as the performance of measures in populations with different social and demographic characteristics, is another important topic area. Furthermore, results from selfadministered interactive computer administration should be compared to results based on traditional in-person interviewer techniques. More research is also needed, both conceptually and empirically, on the relationships among community and patient preferences.
Estimating Costs and Valuing Nonhealth Consequences
In this section, we discuss the development of countryspecific cost catalogues and topics related to consumption costs and productivity effects in the labor market and household. The theoretical rationale for the types of resources to include in (and exclude from) different perspectives is included in Chapter 8 of the full report. 33 Cost catalogues. Costing studies vary with respect to the sources from which unit costs for those resources are derived, thus compromising comparability. While using unit costs specific to decision-making settings, such as particular hospitals or a health care system, would be most appropriate for the analysis, it may be useful to develop a country-specific catalog of unit costs that can be used by all analysts to help standardize CEAs within a country. Such a catalog would include estimates for both health care costs (i.e., direct costs, including the average cost of a physician, inpatient, or emergency room visit) and non-health care costs (i.e., the cost of an arrest or a prison sentence and hourly wages and perperson annual consumption). Some countries (e.g., the United Kingdom), with effectively standardized costs for medicines, hospital procedures, and primary care costs, have already developed or partially developed such a catalog for health sector components. 34 Productivity and consumption costs. For a societal perspective reference case, the Second Panel recommended that productivity benefits of health be explicitly accounted for throughout the life of the patient and that net resource use (i.e., productivity minus consumption) be accounted for during the added years of life from the intervention. This last recommendation has been a point of contention in the literature for some time, with the main debate being why one would account for consumption costs when the utility of consumption is not explicitly accounted for in CEA. [35] [36] [37] As the Second Panel clarifies, CEA can-though need not-be thought of as maximizing health instead of maximizing utility. As described in Meltzer's 1997 article, 38 net resource costs during future years enter the optimality condition through the budget constraint and not the objective function that is being maximized. Thus, consumption costs during added years of life still appear in the calculation of costs even when utility is not maximized.
Others may argue that if changes to consumption due to changes in health (conditional on survival) are explicitly accounted for, then one must also consider the commensurate changes in the utility from changed consumption. 37 Because, at the margin, these changes in consumption and its utility effects should be valued equally by the individual, the optimality condition for medical expenditures does not change if one includes or excludes such adjustments in consumption and utility, as long as the practice is consistent. Thus, CEA can safely ignore both these components and provide consistent metrics for optimal resource allocation in health.
However, in certain cases, changes in health may lead to positive externalities, such as when a new treatment for mental health reduces crime rates. Here the full valuation of these externalities should include not only the total reduction in the policing and criminal justice costs but also the increase in nonhealth outcomes, such as feeling safer and experiencing less crime. Although the Second Panel recognizes that willingness-to-pay measures are one way to value these nonhealth outcomes, other approaches, such as considering outcomes across different sectors, may be feasible, 39 and it would be useful to have more research to understand the existence of these broader psychological impacts from real-world health interventions and also better methods in capturing the health value of these impacts.
Productivity effects and household production. The Second Panel made a judgment that the effects of morbidity on productivity in the labor market and in household production are not captured by standard utility measures and therefore should be assessed in pecuniary terms and included in the numerator of the CEA. There is evidence supporting this judgment, although it is not extensive. [40] [41] [42] [43] Thus, further research on the extent to which respondents incorporate these effects into their responses to health-state valuations is needed. Evidence is also needed on whether and how to inform respondents about the exclusion of such considerations and whether such instructions are effective. Another question exists about whether willingness to pay for an additional life, as reflected in the statistical value-of-life literature, is the appropriate measure to use to value a QALY. Using this metric could reflect double counting of the value of productivity, once through valuing QALYs and the other through explicit accounting for the productivity effects as recommended by the Second Panel.
The Second Panel also recommended a human capital approach to value productivity benefits. In contrast, the friction costs approach suggests that one must account for loss of productivity benefits due to the health of the patient that may be offset by the hiring of a healthy person. It may be useful to better understand nonlabor market productivity among the unemployed in these jurisdictions to approximate better the offset in productivity benefit implied by the rehiring.
More research also is needed to measure changes in household production with specific interventions. Grosse et al., 44 for example, identified the breadth of different household productive activities in which individuals engage at different ages. How these activities change with health and health care interventions may be important in measuring the full productivity benefits of treatment as part of a societal perspective, especially at older ages when productivity benefits would likely come from informal markets and household production.
Evidence Synthesis
Systematic reviews, meta-analyses, and other types of evidence synthesis used in CEA are ad hoc approaches introduced by the evidence-based medicine community to address specific problems but without the benefit of a unifying theory. 45, 46 Currently, there is no rigorous, internally consistent set of premises and theorem-based derivative propositions that motivates and justifies the practice of evidence synthesis. The exception may be the mathematical foundations of quantitative synthesis (meta-analysis). Future research on methodology should develop theory on the underlying problem that evidence synthesis seeks to address and then advance solutions for novel or unmet challenges. Ideally, a theory of evidence synthesis would describe the conditions for learning across studies and the properties of the (similarity) relations that systematic reviewers invoke implicitly when they decide which studies to synthesize, whether and how studies are biased, and whether and how the findings of studies or the evidence synthesis generalize to a target population. [47] [48] [49] Important practical challenges abound. Examples include the combination of data from clinical trials and observational database studies or the estimation of comparative effectiveness where there are no common comparators in a network of treatments. [50] [51] [52] [53] [54] An example of a major unmet challenge is whether treatment effects estimated from one setting are generalizable to a target setting of interest. 55, 56 Despite its importance, this problem is not explicitly addressed in many, if not most, CEA applications. Developing efficient, unbiased estimators for treatment effects in a target setting has remained an active area of research for the past few decades. [57] [58] [59] Novel problems relate to issues such as information synthesis from new types of sources, including large data sets (in which measurement error rather than sampling error is the principal concern), data that change in real time (e.g., data on costs or resource utilization), or data that are available at different levels of granularity (e.g., full information for each observation unit v. partial or coarsened information for each observation v. summary information). Efforts to harness such data to inform policy making are becoming increasingly common. [60] [61] [62] [63] Estimating and Using Cost-effectiveness Thresholds
The concept of a cost-effectiveness threshold has been well understood for many years as the basis of establishing whether an estimated cost-effectiveness ratio is acceptable. 64 However, 2 broad concepts have emerged regarding what this threshold could represent and, consequently, how it can be estimated. 65 The first, termed a ''supply-side'' threshold, reflects the opportunity cost associated with devoting a health system's resources to a particular usehence, the forgone benefits that could have been achieved if the same resources were used for other activities. The second is a ''demand-side'' threshold that relates to the willingness to pay (WTP) for health improvement of a relevant group of individuals (e.g., the general public). One way in which this can be expressed is in terms of the rate at which individuals are willing to forgo other types of consumption to improve their health.
It has been argued that the different concepts inform different resource allocation questions. 66 When informing a health system with a given budget about how to allocate resources, the use of CEA to establish the value of an intervention needs to reflect the benefits that could have been generated if equivalent resources had been used for other purposes in the health system (the supply side concept). Furthermore, by being explicit about opportunity costs, cost-effectiveness and affordability are understood to be part of the same assessment. 67 To say that an intervention ''is cost-effective but not affordable'' must mean that the criteria used to judge costeffectiveness do not reflect the scale and value of the opportunity costs.
Others have argued that understanding a population's WTP is important. For universal health care systems funded through taxation or social insurance, WTP may have a role in informing decisions about the overall funding devoted to health care. In addition, relative WTP for different interventions is also important as it can inform the tradeoffs implicit in forgoing one intervention over another.
For those health systems in which the market plays a key role in determining resource allocation, demand-side tradeoffs (i.e., WTP) play a key role in these allocations. However, in the absence of market-based allocations and where markets are distorted by subsidies and other regulations, as is typically the case in health care, accurate demand-side preferences of the population about relative attributes of interventions are not available. Consequently, after the decision on the total budget is made, a supply-side concept of the threshold, which might be seen as a proxy for consumer preferences, becomes necessary to inform resource allocation decisions. For example, one could measure supply-side opportunity costs based on how providers, as agents for patients, are making decisions about what interventions and benefits are forgone. 68 A key for the research agenda is the empirical representation of these demand and supply concepts. One issue is that the ''threshold'' for decision-making bodies represents something more than opportunity costs or public WTP, reflecting something about other considerations such as the value of innovation. As such, few health systems using CEA are explicit about the magnitude of their ''thresholds,'' and those that are tend to provide no empirical basis. There may, therefore, be a case for more explicit language in this area, avoiding the term threshold and employing more suitable terms for the decision context, such as opportunity cost or public WTP, which may clarify the roles of each in informing different decisions. In terms of empirical research, although researchers have undertaken WTP studies in health care for many years, most have not used a broad measure of health such as the QALY. A recent review of 24 WTP-for-QALY studies indicates substantial variation in results, which was explained by different methods and contexts. 69 In contrast, empirical estimates of the supply-side measure of opportunity cost have only recently emerged, with some studies generating estimates based on the relationship between changes in health expenditure and health outcomes (marginal productivity). 70, 71 There is literature on the expenditure-health outcomes relationship, [72] [73] [74] and earlier work in the United Kingdom provided a foundation for estimates of health opportunity costs in the UK's National Health Service. 70, 75 Although researchers have used these expenditure-health outcomes relationships to provide estimates of opportunity costs internationally, 76 more research along these lines in particular jurisdictions is important.
Another issue is that the estimate of opportunity costs inevitably hinges on provider-level behavior-but how do supply-side incentives and quality-of-care innovations affect this threshold? Should this threshold reflect the marginal technology displaced in clinical practice when budgets are fixed and technology choices are increased v. when technology choices are fixed and budgets change? Finally, it may be useful to explore the practical and political feasibilities of allowing disinvestment decision making at the clinical care level compared to centralized disinvestment targeting the least cost-effective therapy covered.
Reporting and Communicating Costeffectiveness Analyses
The Second Panel deliberated extensively about how prescriptive to be in its recommendations and emphasized in its report that ''striking an appropriate balance between the development of rigorous, high-quality CEAs and the need to provide timely and useful information will be part of ongoing research and dialogue.'' 77 Nonetheless, some observers have expressed concern that the Second Panel's recommendations might be interpreted by journals as prescriptive ''requirements'' or a ''rule book'' for publishing CEAs. 78 The Second Panel continues to believe that its recommendations to report 2 reference case analyses and an Impact Inventory table, which can be included within the main article or a technical appendix, will provide a useful and pragmatic approach that will promote comparability and quality in analyses and serve varied contexts. 77 Written protocols. Despite rapid growth in the publication of CEAs, relatively little research has addressed questions of reporting and communication. The Second Panel recommended that analysts develop a written protocol for the design and conduct of CEAs, arguing that it would improve transparency and credibility by providing editors, reviewers, and readers with a clear description of the goals and methods specified for the analysis at the outset and thus a standard by which to evaluate the results. Although protocols are required for clinical trials and systematic reviews, as is pretrial registration in public registries such as ClinicalTrials.gov, there has been little experience with them for CEA. Important research topics include which components to include in protocols, how analysts should post protocols publicly, and how to assess whether transparency and accountability have been improved. Defining a minimum set of information to include in a posted protocol could be identified through an open deliberative process led by a professional society or other neutral body. A related area pertains to open-source CEA, including publication of the model code (see ''Modeling'').
A key practical barrier is the absence of a central repository for protocols. A potential model is ClinicalTrials.gov. Notably, that resource gained popularity and legitimacy only after journal editors required registration of trials and reporting of results as a condition for publication. For CEAs conducted using data collected prospectively in clinical trials, it may make sense to add protocols for economic evaluations to be submitted along with the main clinical protocol. Entities engaged in producing cost-effectiveness evidence for payers, public or private, could consider establishing a consortium to administer the review and registration of CEA protocols similar to PRISMA. 79 Reporting guidelines and quality measures. Despite the fact that multiple checklists and guidelines on reporting CEAs are available, 1, 2, 17, 80, 81 it is unclear to what extent they have affected reporting practices or influenced decisions. Studies indicate that adherence to reporting recommendations has improved for certain elements in CEAs 82 but still lags in many areas. 83 More important, a checklist does not provide an assessment of the quality of the analysis under consideration.
New research might focus on improvements in quality scoring systems for CEAs to aid decision makers considering economic evidence. A recent study of members of the US Advisory Committee on Immunization Practices, for example, found that committee members wanted more information on the quality of published CEAs and believed that as decision makers, they would benefit if CEAs had a score similar to a scoring system for epidemiologic studies developed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. 84 Some qualityappraisal systems have been proposed for CEAs, 85 but these can be difficult to apply given the broad evidence base, the variable quality of study inputs, and the local nature of decision making. One approach would be to include decision makers in the scoping and development phases of CEAs, as already happens, for example, at the National Institute for Health and Care Excellence (NICE). 34 Such a step could provide an opportunity to improve the CEA protocol. A more comprehensive strategy would involve having models reviewed by trusted independent sources using a standardized scoring system developed and vetted through a consensus process.
Conclusion
Over the past few decades, methods and applications for CEA in health care have advanced. Still, there are many areas for further research and policy development. The deliberations of the Second Panel on Cost-effectiveness in Health and Medicine identified several key topics that arose during the panel's discussions and for which the panel believes that future work would be particularly fruitful. In terms of methods development, we highlighted key questions related to valuing health and nonhealth outcomes, costing, modeling, estimating and using CEA thresholds, reporting and communicating CEAs, and broadening criteria used to assess cost-effectiveness. More work is needed on many fronts to understand how best to incorporate CEA in practice.
